Alzinova (ALZ) Q2 2026 earnings summary

Executive summary

• Advanced collaboration with Amsterdam UMC to develop a blood-based diagnostic test for Alzheimer's, aiming for early-stage identification and faster market entry.

• Entered a Letter of Intent with Fujirebio for potential development and commercialization of the diagnostic test, with validation results expected in Q3 2026.

• Published positive Phase 1b clinical results for ALZ-101 in a peer-reviewed journal, reinforcing scientific credibility.

• Continued preparations for ALZ-101 Phase II, including manufacturing scale-up and regulatory activities.

Financial highlights

• Loss after financial items for Q2 2026 was SEK -5,449 thousand, improved from SEK -7,684 thousand in Q2 2025.

• Six-month loss after financial items was SEK -11,473 thousand, compared to SEK -13,415 thousand year-over-year.

• Cash flow for Q2 2026 was SEK 1,927 thousand (Q2 2025: SEK 7,918 thousand); six-month cash flow was SEK 12,989 thousand (2025: SEK -3,986 thousand).

• Cash and cash equivalents at period end were SEK 13,309 thousand, up from SEK 11,510 thousand a year earlier.

• Total expenses for Q2 2026 were SEK -8,490 thousand, with R&D costs of SEK -3,066 thousand.

Outlook and guidance

• Initial validation results for the blood-based diagnostic test expected in Q3 2026, potentially leading to a definitive collaboration and licensing agreement.

• Preparations for ALZ-101 Phase II continue, with ongoing partner discussions and focus on advancing both therapeutic and diagnostic programs.